SLC5A2 and diabetes mellitus: Compared with the results of the EMPA-REG Outcome Trial, canagliflozin showed a similar improvement in cardiovascular outcomes and kidney disease risk in patients with DM, but it significantly increased amputation and fracture rates in these patients, which has not been reported thus far in the cardiovascular outcomes trials of other SGLT2 inhibitors [86].